Therapeutic potential of TAK-071, a muscarinic M1 receptor positive allosteric modulator with low cooperativity, for the treatment of cognitive deficits and negative symptoms associated with schizophrenia. (1st November 2021)

• Record Type: Journal Article
• Authors: Kurimoto, Emi; Yamada, Ryuji; Hirakawa, Takeshi; Kimura, Haruhide
• Is Part Of: Neuroscience letters. Volume 764(2021)
• Publication Date: 2021-11-01
• Subjects: CIAS cognitive impairment associated with schizophrenia -- GI gastrointestine -- LTD long-term depression -- METH methamphetamine -- MiR-137 microRNA-137 -- MK-7622 3-((1S, 2S)-2-hydroxycyclohexyl)-6-((6-methylpyridin-3 yl)methyl)benzo[h]quinazolin-4(3H)-one) -- M1 PAM M1 muscarinic receptor positive allosteric modulator -- poly I:C polyriboinosinic-polyribocytidylic acid -- TAK-071 (4-fluoro-2-[(3S, 4S)-4-hydroxytetrahydro-2H-pyran-3-yl]-5-methyl-6-[4-(1H-pyrazol-1-yl)benzyl]-2, 3-dihydro-1H-isoindol-1-one); TAK-071 -- Muscarinic M1 receptor -- Positive allosteric modulator -- Low cooperativity -- Cognitive impairment associated with schizophrenia -- Negative symptom; Neurology -- Periodicals; Neurology -- Periodicals; Research -- Periodicals; Neurologie -- Périodiques; Neuroanatomie -- Périodiques; Neuropharmacologie -- Périodiques; Neurophysiologie -- Périodiques; Neurology; Periodicals; Electronic journals; 617.48
• DOI: 10.1016/j.neulet.2021.136240
• Languages: English
• ISSNs: 0304-3940

Abstract

Highlights: TAK-071 improved working memory, sociability, and sensorimotor gating. TAK-071 reversed olanzapine- and quetiapine-induced M1 R antagonism. Haloperidol did not affect TAK-071-induced cognitive improvement. Abstract: The selective activation of the muscarinic M1 receptor (M1 R) may be a promising approach for treating cognitive impairment associated with cholinergic dysfunction. We previously reported that low cooperativity (α-value) is associated with a favorable cholinergic side effect profile of M1 R positive allosteric modulators (M1 PAMs), as well as being a crucial factor for the cognitive improvement observed after combining M1 PAMs with donepezil, in rodents. In this study, we preclinically characterized TAK-071, a novel M1 PAM with low cooperativity (α-value = 199), as a new therapy for schizophrenia. We tested TAK-071 in the offspring of polyriboinosinic-polyribocytidylic acid-treated dams, which is a maternal immune activation model of schizophrenia. TAK-071 improved sociability deficits and working memory in this model. In a genetic mouse model of schizophrenia, miR-137 transgenic (Tg) mice, TAK-071 improved deficits in working memory, recognition memory, sociability, and sensorimotor gating. Patients with schizophrenia usually take several antipsychotics to treat positive symptoms. Thus, we also investigated the combined effects of TAK-071 with currently prescribed antipsychotics. Among the 10 antipsychotics tested, only olanzapine and quetiapine showed M1 R antagonistic effects, which were counteracted by TAK-071 at possible effective concentrations for cognitive improvement in vitro . Moreover, haloperidol did not affect the ability of TAK-071 to improve working memory in miR-137 Tg mice, suggesting a low risk of losing efficacy when combined with dopamine D2 receptor antagonists. In conclusion, TAK-071 can exert beneficial effects on social behavior and cognitive function and could be a new therapy for schizophrenia.